Signs of strain and resilience in biotech’s crossover crowd

An analysis of public equity positions held by biopharma’s most active crossover investors suggests that most are not in imminent danger. although a few appear to be under financial pressure, with one possibly in more trouble than the others.

Amid a flood of rumors about the health of influential biotech investors, BioCentury undertook an analysis of 13F filings by a select group of firms to identify potential indicators of financial distress. The SEC-mandated filings detail a firm’s holdings in publicly traded companies listed on U.S. exchanges...